ProShare Advisors
TERN

ProShare Advisors’s Terns Pharmaceuticals TERN Stock Holding History

ProShare Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Buy
25,571
+5,917
+30% +$243K ﹤0.01% 738
2025
Q4 		$794K Buy
19,654
+4,173
+27% +$96.4K ﹤0.01% 902
2025
Q3 		$116K Sell
15,481
-2,608
-14% -$16.7K ﹤0.01% 1818
2025
Q2 		$67.5K Sell
18,089
-962
-5% -$3K ﹤0.01% 1949
2025
Q1 		$52.6K Sell
19,051
-4,770
-20% -$19.5K ﹤0.01% 1952
2024
Q4 		$132K Buy
23,821
+8,784
+58% +$59.5K ﹤0.01% 2009
2024
Q3 		$125K Buy
+15,037
New +$124K ﹤0.01% 1846
2024
Q2 		– Sell
-12,121
Closed -$79.5K – 2002
2024
Q1 		$79.5K Buy
12,121
+1,079
+10% +$7.05K ﹤0.01% 1855
2023
Q4 		$71.7K Buy
+11,042
New +$58.4K ﹤0.01% 1822

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

ProShare Advisors's TERN Position: Q1 2026 in Review

ProShare Advisors increased its Terns Pharmaceuticals (TERN) stake by 30% in Q1 2026, buying an estimated $243K and bringing the position to 25,571 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #738.

ProShare Advisors first reported a position in TERN in Q4 2023 and has held it in 9 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • ProShare Advisors held 25,571 shares of Terns Pharmaceuticals worth $1.35M as of Q1 2026.
  • ProShare Advisors bought 5,917 Terns Pharmaceuticals shares in Q1 2026, an estimated $243K.
  • Terns Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #738 holding.
  • ProShare Advisors first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.